AAPL330.49+5.53 (+1.70%) ▲|ABBV260.68-1.04 (-0.40%) ▼|ABT108.84-1.63 (-1.48%) ▼|ACN193.90+6.22 (+3.31%) ▲|ADBE286.31+6.52 (+2.33%) ▲|AMAT435.32-3.14 (-0.72%) ▼|AMD455.80-1.26 (-0.28%) ▼|AMGN442.90+0.06 (+0.01%) ▲|AMT177.25+4.33 (+2.50%) ▲|AMZN258.65+3.67 (+1.44%) ▲|AVGO347.54-19.70 (-5.36%) ▼|AXP330.52+0.54 (+0.16%) ▲|BA207.07-1.80 (-0.86%) ▼|BAC63.11+0.51 (+0.81%) ▲|BKNG198.54-1.06 (-0.53%) ▼|BLK1,116.05+8.97 (+0.81%) ▲|BMY67.55-0.12 (-0.17%) ▼|BNY164.22+2.18 (+1.34%) ▲|BRK-B507.61+2.37 (+0.47%) ▲|C137.73+3.39 (+2.52%) ▲|CAT801.00+8.72 (+1.10%) ▲|CL90.27+0.17 (+0.19%) ▲|CMCSA26.59-0.23 (-0.84%) ▼|COF218.97+2.37 (+1.09%) ▲|COP137.07-0.13 (-0.09%) ▼|COST927.05-1.43 (-0.15%) ▼|CRM264.22+7.29 (+2.84%) ▲|CSCO109.37-0.09 (-0.08%) ▼|CVS97.60+0.37 (+0.38%) ▲|CVX213.02+1.24 (+0.59%) ▲|DE692.91-5.46 (-0.78%) ▼|DHR208.92-0.99 (-0.47%) ▼|DIS107.82-0.16 (-0.15%) ▼|DUK121.56+1.00 (+0.83%) ▲|EMR149.58+0.60 (+0.40%) ▲|FDX320.38+3.84 (+1.21%) ▲|GD362.48-1.59 (-0.44%) ▼|GE332.37+2.87 (+0.87%) ▲|GEV945.25+23.31 (+2.53%) ▲|GILD149.98+0.37 (+0.24%) ▲|GM86.26+1.39 (+1.64%) ▲|GOOG339.54+5.76 (+1.73%) ▲|GOOGL343.03+5.91 (+1.75%) ▲|GS1,036.64+32.22 (+3.21%) ▲|HD317.86+1.68 (+0.53%) ▲|HON206.83+0.76 (+0.37%) ▲|IBM235.25+3.55 (+1.53%) ▲|INTC90.14+0.09 (+0.10%) ▲|INTU349.34+6.40 (+1.87%) ▲|ISRG368.79-3.09 (-0.83%) ▼|JNJ278.07+2.86 (+1.04%) ▲|JPM361.62+5.40 (+1.52%) ▲|KO88.92+0.68 (+0.77%) ▲|LIN483.75-2.10 (-0.43%) ▼|LLY1,152.68-7.41 (-0.64%) ▼|LMT530.78-0.77 (-0.14%) ▼|LOW200.94+1.10 (+0.55%) ▲|LRCX286.57-1.75 (-0.61%) ▼|MA587.11-1.04 (-0.18%) ▼|MCD258.47-2.48 (-0.95%) ▼|MDLZ61.29-1.16 (-1.86%) ▼|MDT92.41+0.23 (+0.24%) ▲|META618.98+26.13 (+4.41%) ▲|MMM167.34-1.41 (-0.84%) ▼|MO69.78+0.22 (+0.32%) ▲|MRK150.44-1.20 (-0.79%) ▼|MS216.99+5.17 (+2.44%) ▲|MSFT512.81+15.99 (+3.22%) ▲|MU945.27-10.81 (-1.13%) ▼|NEE84.11+1.01 (+1.21%) ▲|NFLX82.56-0.17 (-0.21%) ▼|NKE38.21-0.03 (-0.07%) ▼|NOW143.79+7.07 (+5.17%) ▲|NVDA226.98+2.57 (+1.14%) ▲|ORCL152.30+6.55 (+4.49%) ▲|PEP139.66-0.87 (-0.62%) ▼|PFE28.73-0.30 (-1.02%) ▼|PG147.15-0.49 (-0.33%) ▼|PLTR183.42+13.96 (+8.24%) ▲|PM188.56+0.62 (+0.33%) ▲|QCOM169.19+0.15 (+0.09%) ▲|RTX201.25+0.47 (+0.23%) ▲|SBUX106.03-0.69 (-0.65%) ▼|SCHW110.10+1.86 (+1.71%) ▲|SO89.07+0.76 (+0.86%) ▲|SPG211.54+1.34 (+0.64%) ▲|T25.89-0.07 (-0.25%) ▼|TMO611.47+2.93 (+0.48%) ▲|TMUS188.01+0.71 (+0.38%) ▲|TSLA380.40+23.39 (+6.55%) ▲|TXN252.48-2.32 (-0.91%) ▼|UBER75.60-0.86 (-1.12%) ▼|UNH404.94+5.28 (+1.32%) ▲|UNP290.56+0.83 (+0.29%) ▲|UPS102.78-0.23 (-0.22%) ▼|USB63.38+0.61 (+0.96%) ▲|V379.41+1.01 (+0.27%) ▲|VZ50.21-0.01 (-0.02%) ▼|WFC89.61+0.34 (+0.38%) ▲|WMT108.98+2.89 (+2.72%) ▲|XOM164.38+0.23 (+0.14%) ▲|AAPL330.49+5.53 (+1.70%) ▲|ABBV260.68-1.04 (-0.40%) ▼|ABT108.84-1.63 (-1.48%) ▼|ACN193.90+6.22 (+3.31%) ▲|ADBE286.31+6.52 (+2.33%) ▲|AMAT435.32-3.14 (-0.72%) ▼|AMD455.80-1.26 (-0.28%) ▼|AMGN442.90+0.06 (+0.01%) ▲|AMT177.25+4.33 (+2.50%) ▲|AMZN258.65+3.67 (+1.44%) ▲|AVGO347.54-19.70 (-5.36%) ▼|AXP330.52+0.54 (+0.16%) ▲|BA207.07-1.80 (-0.86%) ▼|BAC63.11+0.51 (+0.81%) ▲|BKNG198.54-1.06 (-0.53%) ▼|BLK1,116.05+8.97 (+0.81%) ▲|BMY67.55-0.12 (-0.17%) ▼|BNY164.22+2.18 (+1.34%) ▲|BRK-B507.61+2.37 (+0.47%) ▲|C137.73+3.39 (+2.52%) ▲|CAT801.00+8.72 (+1.10%) ▲|CL90.27+0.17 (+0.19%) ▲|CMCSA26.59-0.23 (-0.84%) ▼|COF218.97+2.37 (+1.09%) ▲|COP137.07-0.13 (-0.09%) ▼|COST927.05-1.43 (-0.15%) ▼|CRM264.22+7.29 (+2.84%) ▲|CSCO109.37-0.09 (-0.08%) ▼|CVS97.60+0.37 (+0.38%) ▲|CVX213.02+1.24 (+0.59%) ▲|DE692.91-5.46 (-0.78%) ▼|DHR208.92-0.99 (-0.47%) ▼|DIS107.82-0.16 (-0.15%) ▼|DUK121.56+1.00 (+0.83%) ▲|EMR149.58+0.60 (+0.40%) ▲|FDX320.38+3.84 (+1.21%) ▲|GD362.48-1.59 (-0.44%) ▼|GE332.37+2.87 (+0.87%) ▲|GEV945.25+23.31 (+2.53%) ▲|GILD149.98+0.37 (+0.24%) ▲|GM86.26+1.39 (+1.64%) ▲|GOOG339.54+5.76 (+1.73%) ▲|GOOGL343.03+5.91 (+1.75%) ▲|GS1,036.64+32.22 (+3.21%) ▲|HD317.86+1.68 (+0.53%) ▲|HON206.83+0.76 (+0.37%) ▲|IBM235.25+3.55 (+1.53%) ▲|INTC90.14+0.09 (+0.10%) ▲|INTU349.34+6.40 (+1.87%) ▲|ISRG368.79-3.09 (-0.83%) ▼|JNJ278.07+2.86 (+1.04%) ▲|JPM361.62+5.40 (+1.52%) ▲|KO88.92+0.68 (+0.77%) ▲|LIN483.75-2.10 (-0.43%) ▼|LLY1,152.68-7.41 (-0.64%) ▼|LMT530.78-0.77 (-0.14%) ▼|LOW200.94+1.10 (+0.55%) ▲|LRCX286.57-1.75 (-0.61%) ▼|MA587.11-1.04 (-0.18%) ▼|MCD258.47-2.48 (-0.95%) ▼|MDLZ61.29-1.16 (-1.86%) ▼|MDT92.41+0.23 (+0.24%) ▲|META618.98+26.13 (+4.41%) ▲|MMM167.34-1.41 (-0.84%) ▼|MO69.78+0.22 (+0.32%) ▲|MRK150.44-1.20 (-0.79%) ▼|MS216.99+5.17 (+2.44%) ▲|MSFT512.81+15.99 (+3.22%) ▲|MU945.27-10.81 (-1.13%) ▼|NEE84.11+1.01 (+1.21%) ▲|NFLX82.56-0.17 (-0.21%) ▼|NKE38.21-0.03 (-0.07%) ▼|NOW143.79+7.07 (+5.17%) ▲|NVDA226.98+2.57 (+1.14%) ▲|ORCL152.30+6.55 (+4.49%) ▲|PEP139.66-0.87 (-0.62%) ▼|PFE28.73-0.30 (-1.02%) ▼|PG147.15-0.49 (-0.33%) ▼|PLTR183.42+13.96 (+8.24%) ▲|PM188.56+0.62 (+0.33%) ▲|QCOM169.19+0.15 (+0.09%) ▲|RTX201.25+0.47 (+0.23%) ▲|SBUX106.03-0.69 (-0.65%) ▼|SCHW110.10+1.86 (+1.71%) ▲|SO89.07+0.76 (+0.86%) ▲|SPG211.54+1.34 (+0.64%) ▲|T25.89-0.07 (-0.25%) ▼|TMO611.47+2.93 (+0.48%) ▲|TMUS188.01+0.71 (+0.38%) ▲|TSLA380.40+23.39 (+6.55%) ▲|TXN252.48-2.32 (-0.91%) ▼|UBER75.60-0.86 (-1.12%) ▼|UNH404.94+5.28 (+1.32%) ▲|UNP290.56+0.83 (+0.29%) ▲|UPS102.78-0.23 (-0.22%) ▼|USB63.38+0.61 (+0.96%) ▲|V379.41+1.01 (+0.27%) ▲|VZ50.21-0.01 (-0.02%) ▼|WFC89.61+0.34 (+0.38%) ▲|WMT108.98+2.89 (+2.72%) ▲|XOM164.38+0.23 (+0.14%) ▲|

25.1 C

New York

Thursday, September 3, 2026

ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages Pentair plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – PNR

DDNYC 2026 Draws Record Attendance as Thousands Pack New York for Doginal Dogs’ Flagship Event

Fitness Ventures, Largest Crunch Fitness Franchisee, brings 106 Crunch Fitness Locations and 100+ Fire Departments Together for Nationwide 9/11 Remembrance Stair Climb Challenge

Tag: tumor

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

Technetium-99m Market Size to Reach USD 6.29 Billion by 2031, Growing at a CAGR of 3.9% | Exclusive Report by The Insight Partners

NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global technetium-99m market is witnessing substantial...

Technetium-99m Market Size to Reach USD 6.29 Billion by 2031, Growing at a CAGR of 3.9% | Exclusive Report by The Insight Partners

NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global technetium-99m market is witnessing substantial...

Nature Medicine Published Phase 1 Results of Innovent Biologics’ Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality...

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER. BC, July 16, 2025 /PRNewswire/ -- As lawmakers weigh potential cuts to scientific research...

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER. BC, July 16, 2025 /PRNewswire/ -- As lawmakers weigh potential cuts to scientific research...

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER. BC, July 16, 2025 /CNW/ -- As lawmakers weigh potential cuts to scientific research...

Senhwa Biosciences announces first patient dosed in NCI-sponsored pilot study of Pidnarulex (CX-5461) pharmacodynamics in patients with advanced solid tumors

TAIPEI and SAN DIEGO, July 15, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for...

Akeso Announces First Patient Enrolled in the Phase III Trial（AK112-312/HARMONi-GI6）of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

HONG KONG, July 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been successfully...

BIOVAXYS ANNOUNCES EXTENSION OF OFFERING CLOSING DATE

// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, July 15, 2025 /PRNewswire/ -- BioVaxys...

BIOVAXYS ANNOUNCES EXTENSION OF OFFERING CLOSING DATE

// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, July 15, 2025 /CNW/ -- BioVaxys...

Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight

The menin inhibitor market is poised for rapid growth, with REVUFORJ setting the foundation and a strong pipeline of innovative, genetically targeted therapies on...

Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight

The menin inhibitor market is poised for rapid growth, with REVUFORJ setting the foundation and a strong pipeline of innovative, genetically targeted therapies on...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsTumor

ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages Pentair plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – PNR

DDNYC 2026 Draws Record Attendance as Thousands Pack New York for Doginal Dogs’ Flagship Event

Fitness Ventures, Largest Crunch Fitness Franchisee, brings 106 Crunch Fitness Locations and 100+ Fire Departments Together for Nationwide 9/11 Remembrance Stair Climb Challenge

Tag: tumor

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

Technetium-99m Market Size to Reach USD 6.29 Billion by 2031, Growing at a CAGR of 3.9% | Exclusive Report by The Insight Partners

Technetium-99m Market Size to Reach USD 6.29 Billion by 2031, Growing at a CAGR of 3.9% | Exclusive Report by The Insight Partners

Nature Medicine Published Phase 1 Results of Innovent Biologics’ Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

Senhwa Biosciences announces first patient dosed in NCI-sponsored pilot study of Pidnarulex (CX-5461) pharmacodynamics in patients with advanced solid tumors

Akeso Announces First Patient Enrolled in the Phase III Trial（AK112-312/HARMONi-GI6）of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

BIOVAXYS ANNOUNCES EXTENSION OF OFFERING CLOSING DATE

BIOVAXYS ANNOUNCES EXTENSION OF OFFERING CLOSING DATE

Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight

Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us